Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy.

IF 12.8 1区医学 Q1 DERMATOLOGY

Journal of the American Academy of Dermatology Pub Date : 2025-03-10 DOI:10.1016/j.jaad.2025.03.006

Kelly G Paulson, Song Y Park, Shailender Bhatia, Daniel S Hippe, Paul Nghiem

{"title":"Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy.","authors":"Kelly G Paulson, Song Y Park, Shailender Bhatia, Daniel S Hippe, Paul Nghiem","doi":"10.1016/j.jaad.2025.03.006","DOIUrl":null,"url":null,"abstract":"Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer with poor survival rates. Immune checkpoint inhibitors (ICIs) were FDA-approved for advanced MCC in 2017, but their real-world survival impact remains unclear.Objective: Evaluate whether ICI introduction in the US corresponded with improved survival.Methods: This cohort study analyzed SEER data for MCC patients diagnosed from 2010 to 2021, grouped by 3-year periods, to calculate 2-year overall and relative survival.Results: For 453 patients with metastatic MCC, 2-year relative survival improved from 23% (2010-2012) to 37% (2013-2015), 42% (2016-2018), and 54% (2019-2021) (p < 0.001). Median overall survival also increased from 9 to 16 months among these patients. In 4,786 MCC patients overall, 2-year relative survival rose from 73% (2010-2012) to 81% (2019-2021) (p = 0.004), while overall survival improved from 67% to 72% (p = 0.012).Limitations: SEER lacks case-level data to link ICI treatment directly to survival, although ICIs represent the major recent treatment advance for MCC.Conclusions: The introduction of ICIs aligns with a >2-fold increase in survival for advanced MCC patients at the population level, translating to ∼220 fewer deaths per year in the U.S.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaad.2025.03.006","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer with poor survival rates. Immune checkpoint inhibitors (ICIs) were FDA-approved for advanced MCC in 2017, but their real-world survival impact remains unclear.

Objective: Evaluate whether ICI introduction in the US corresponded with improved survival.

Methods: This cohort study analyzed SEER data for MCC patients diagnosed from 2010 to 2021, grouped by 3-year periods, to calculate 2-year overall and relative survival.

Results: For 453 patients with metastatic MCC, 2-year relative survival improved from 23% (2010-2012) to 37% (2013-2015), 42% (2016-2018), and 54% (2019-2021) (p < 0.001). Median overall survival also increased from 9 to 16 months among these patients. In 4,786 MCC patients overall, 2-year relative survival rose from 73% (2010-2012) to 81% (2019-2021) (p = 0.004), while overall survival improved from 67% to 72% (p = 0.012).

Limitations: SEER lacks case-level data to link ICI treatment directly to survival, although ICIs represent the major recent treatment advance for MCC.

Conclusions: The introduction of ICIs aligns with a >2-fold increase in survival for advanced MCC patients at the population level, translating to ∼220 fewer deaths per year in the U.S.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Academy of Dermatology 医学-皮肤病学

CiteScore

8.60

自引率

5.80%

发文量

2023

审稿时长

49 days

期刊介绍： The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.